Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nitric oxide inhalation - Beyond Air

Drug Profile

Nitric oxide inhalation - Beyond Air

Alternative Names: AIT-BRO; AIT-CF; AIT-COPD; AIT-NTM; AIT-NV; AIT-RSV; AIT-WH; iNO - Beyond Air™; Nitric oxide inhaled; NOxAST; NOxBR; NOxCF; NOxCureBR; NOxCureCF; NOxPN

Latest Information Update: 12 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of British Columbia
  • Developer Beyond Air; Schneider Childrens Medical Center of Israel; University of British Columbia
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antivirals; Cardiovascular therapies; Diagnostic agents; Free radicals; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Nitric oxide donors; Reactive oxygen species modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mycobacterial infections; Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bronchitis
  • Phase II Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetic foot ulcer; Mycobacterial infections; Stroke
  • Clinical Phase Unknown COVID 2019 infections
  • Preclinical Solid tumours
  • No development reported Respiratory tract infections
  • Discontinued Asthma; Pneumonia

Most Recent Events

  • 22 Jun 2020 Beyond Air plans a pivotal LungFit™ HOME trial for Mycobacterial infections by the end of 2020 (Inhalation)
  • 22 Jun 2020 The Health Canada approves a Clinical Trial Application for Nitric oxide inhaled in COVID-2019 infections before March 2020
  • 22 Jun 2020 Efficacy and safety data from a phase II trial in Bronchitis (Acute bronchiolitis) released by Beyond Air
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top